Picture EBD Group ChinaBio Partnerting Forum 2021 651x80
Organisation › Details

Pharvaris B.V.

Pharvaris is a clinical-stage company focused on bringing oral B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, we are progressing new alternatives to injected therapies for all sub-types of HAE and other B2-receptor-mediated indications. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. *


Period Start 2016-04-07 existent
Products Industry pharmaceutical
  Industry 2 PHA121 (incl in soft capsules as PHVS416) (Pharvaris)
Persons Person Modig, Berndt (Pharvaris CEO before Prosensa 201003 CFO before Jerini 200310– CFO before Surplex AG)
  Person 2 Knolle, Jochen (Kurma Partners 201901 at Munich Office before Jerini 2000– before Axys + Hoechst)
Region Region Netherlands_oo
  Country Netherlands
  Street 21 J.H. Oortweg
  City 2333 CH Leiden
    Address record changed: 2020-12-02
Basic data Employees n. a.
    * Document for �About Section�: Pharvaris B.V.. (9/10/19). "Press Release: Pharvaris Announces $66 Million Series B Financing to Advance the Clinical Development of an Oral Therapy for Hereditary Angioedema". Leiden.
Record changed: 2020-11-21


Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Pharvaris B.V.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Back into Ad 650x80px

» top